Latest News
Cerenis Therapeutics to Terminate Proposed Merger with H4Orphan Pharma
Thursday 18 April 2019

18 April 2019 - French biopharmaceutical company Cerenis Therapeutics has decided to terminate a proposed merger with French biotech startup H4Orphan Pharma, the companies said.

In March, the companies entered into exclusive negotiations.

This combination was to have taken the form of an absorption of H4 Orphan Pharma by Cerenis Therapeutics, the shares of which are listed on Euronext.

If this transaction is completed, Cerenis Therapeutics' shareholders would hold 59% of the merged entity and those of H4Orphan Pharma 41%.

Cerenis cited difficulties in the governance of the proposed merged company as its reason for nixing the deal.

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company focused on the discovery and development of HDL-based innovative therapies.
Date Published: 18/04/2019
Target: H4Orphan Pharma
Country: France
Sector: Biotechnology
Type: Merger
Financing: Stock
Status: Agreed
Buyer: Cerenis Therapeutics,  
Terms of the deal were not disclosed